Archives

  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • br Figure ROC analysis for miR a as

    2020-08-12


    Figure 3. ROC analysis for miR-196a as a diagnostic biomarker for malignancy in biliary brushings.
    Sensitivity is plotted versus 100% - specificity.
    LEGEND TO SUPPLEMENTARY FIGURE
    Supplementary Figure 1.
    Box plot presentation of threshold 25126-32-3 differences between malignant and benign pancreatobiliary samples for target microRNAs (miR-16, miR-21, miR-196a, miR-221). Normalized (∆Ct) expression values were all depicted after subtraction from 40, therefore a higher number reflects higher expression. Sample size is n=35.
    ACCEPTED MANUSCRIPT
    malignant biliary malignant pancreatic benign pancreatobiliary
    strictures strictures strictures
    9/14 distal bile duct 8/12 pancreatic head 6/9 chronic pancreatitis
    Diagnosis n (%) 5/14 perihilar bile duct 4/12 pancreatic body/tail 1/9 pseudocyst
    1/9 cystadenoma serosum
    1/9 cholelithiasis
    intervention (month) ♯
    Table 1. Clinical characteristics of the patients.
    ♯ = mean ± SD; § American Joint Committee on Cancer (AJCC) TNM Staging of Pancreatic Cancer and Bile Duct Tumors (2010), * pre-ERCP values
    ACCEPTED MANUSCRIPT
    Cytology miR-16 miR-196a miR-221 Combined expression profiles Cytology + Cytology +
    miR- 196a miR expression
    1 positive 2 positive 3 positive
    Table 2. Diagnostic utility of single and combined microRNA markers in the entire group of strictures.
    PPV = positive predictive value, NPV = negative predictive value, miR = mature microRNA
    ACCEPTED MANUSCRIPT
    Cytology miR-16 miR-196a miR-221 Combined expression profiles Cytology + Cytology +
    miR-16 miR expression
    1 positive 2 positive 3 positive
    Table 3. Diagnostic utility of single and combined microRNA markers in pancreatic strictures.
    PPV = positive predictive value, NPV = negative predictive value, miR = mature microRNA
    ACCEPTED MANUSCRIPT
    Cytology miR-16 miR-196a miR-221 Combined expression profiles Cytology + Cytology +
    miR-196a miR expression
    1 positive 2 positive 3 positive
    Table 4. Diagnostic utility of single and combined microRNA markers in biliary strictures.
    PPV = positive predictive value, NPV = negative predictive value, miR = mature microRNA
    ACCEPTED MANUSCRIPT
    miRNA
    Stem Loop Sequence
    Mature
    Assay ID# Catalogue
    sequence
    GUCAGCAGUGCCUUAGCAG
    UAGCAGCACG
    CACGUAAAUAUUGGCGUUA
    UAAAUAUUGG
    AGAUUCUAAAAUUAUCUCC
    CG
    AGUAUUAACUGUGCUGCUG
    AAGUAAGGUUGAC
    UGUCGGGUAGCUUAUCAGA
    UAGCUUAUCA
    CUGAUGUUGACUGUUGAAU
    GACUGAUGUU
    CUCAUGGCAACACCAGUCG
    GA
    AUGGGCUGUCUGACA
    GUGAAUUAGGUAGUUUCAU
    UAGGUAGUUU
    GUUGUUGGGCCUGGGUUUC
    CAUGUUGUUG
    UGAACACAACAACAUUAAA
    GG
    CCACCCGAUUCAC
    UGAACAUCCAGGUCUGGGG
    AGCUACAUUG
    CAUGAACCUGGCAUACAAU
    UCUGCUGGGU
    GUAGAUUUCUGUGUUCGUU
    UUC
    AGGCAACAGCUACAUUGUC
    UGCUGGGUUUCAGGCUACC
    UGGAAACAUGUUCUC
    RNU6B
    (not available)
    CGCAAGGATG
    ACACGCAAAT
    TCGTGAAGCG
    TTCCATATTTT
    T
    Supplementary Table 1 – Primers used for Taqman mic roRNA PCR assays. # ThermoFisher Scientific product information
    ACCEPTED MANUSCRIPT
    ACCEPTED MANUSCRIPT
    ACCEPTED MANUSCRIPT
    Contents lists available at ScienceDirect
    Gynecologic Oncology
    Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression
    Charles W. Ashley a,1, Arnaud Da Cruz Paula a,1, Rahul Kumar b, Diana Mandelker b, Xin Pei c, Nadeem Riaz c, Jorge S. Reis-Filho b, Britta Weigelt b,
    a Department of Surgery, Gynecology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    b Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    c Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    • MSI and POLE endometrial cancers (ECs) show specific mutational signatures.
    • The majority of ECs and carcinosarcomas display the aging-associated signature 1.
    • POLE mutations have an allele-specific impact on mutational processes.
    • 15% of serous-like ECs have the defective homologous recombination DNA repair signature 3.
    • Shifts in the mutational signatures take place in the progression of ECs.
    Article history:
    Keywords:
    Endometrial cancer
    Carcinosarcoma
    Mutational signatures
    Metastasis
    Molecular subtypes 
    Objective. Mutational signatures provide insights into the biological processes shaping tumor genomes and may inform patient therapy. We sought to define the mutational signatures of i) endometrioid and serous endo-metrial carcinomas (ECs), stratified into the four molecular subtypes, ii) uterine carcinosarcomas, and iii) matched primary and metastatic ECs.